Nombre del producto:(R)-3-Boc-AMinopiperidine

IUPAC Name:tert-butyl N-[(3R)-piperidin-3-yl]carbamate

CAS:309956-78-3
Fórmula molecular:C10H20N2O2
Pureza:97%
Número de catálogo:CM101941
Peso molecular:200.28

Unidad de embalaje Stock disponible Precio($) Cantidad
CM101941-100g in stock Łţţ
CM101941-500g in stock ǎħƴ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :309956-78-3
Fórmula molecular:C10H20N2O2
Punto de fusión:-
Código de sonrisas:O=C(N[C@H]1CNCCC1)OC(C)(C)C
Densidad:
Número de catálogo:CM101941
Peso molecular:200.28
Punto de ebullición:
Nº Mdl:MFCD03093382
Almacenamiento:Store at room temperature.

Category Infos

Piperidines
Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.
Piperidine,Piperidine Price
if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.

Column Infos

BMF-219
Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.
JNT-517
Jnana Therapeutics announced positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with phenylketonuria (PKU). JNT-517, a small molecule inhibitor of the phenylalanine (Phe) transporter SLC6A19, is being evaluated as a potential first-in-class oral treatment for PKU across all ages and genotypes. Based on these positive mid-term results, Jnana has adjusted its phase 1b clinical trial design to support the critical phase 3 clinical trial of JNT-517 starting in the first half of 2025.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products